Vestal Point Capital LP Decreases Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Vestal Point Capital LP reduced its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 31.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,500,000 shares of the company’s stock after selling 700,000 shares during the period. Vestal Point Capital LP’s holdings in Allogene Therapeutics were worth $4,200,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ALLO. CANADA LIFE ASSURANCE Co raised its stake in shares of Allogene Therapeutics by 85.1% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 17,750 shares of the company’s stock worth $79,000 after buying an additional 8,162 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Allogene Therapeutics by 76.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,177,619 shares of the company’s stock worth $18,675,000 after acquiring an additional 1,806,147 shares during the last quarter. Bourgeon Capital Management LLC raised its position in Allogene Therapeutics by 131.6% during the second quarter. Bourgeon Capital Management LLC now owns 132,455 shares of the company’s stock worth $309,000 after acquiring an additional 75,255 shares during the last quarter. Phoenix Wealth Advisors purchased a new stake in shares of Allogene Therapeutics in the second quarter valued at about $30,000. Finally, Nisa Investment Advisors LLC grew its position in shares of Allogene Therapeutics by 429.6% in the second quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock valued at $25,000 after purchasing an additional 8,734 shares during the last quarter. 83.63% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently issued reports on ALLO shares. Truist Financial restated a “buy” rating and set a $14.00 price objective (down from $17.00) on shares of Allogene Therapeutics in a research report on Friday, August 9th. Oppenheimer started coverage on Allogene Therapeutics in a research report on Thursday, August 8th. They issued an “outperform” rating and a $11.00 price objective on the stock. Canaccord Genuity Group decreased their price objective on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. Citigroup boosted their target price on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Allogene Therapeutics in a research note on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $9.73.

Allogene Therapeutics Price Performance

ALLO opened at $2.50 on Friday. Allogene Therapeutics, Inc. has a 1 year low of $1.99 and a 1 year high of $5.78. The company’s 50 day simple moving average is $2.66 and its 200 day simple moving average is $2.62.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).